Taking HRT and GLP-1 Treatment Together

HRT treats symptoms associated with menopause and can help prevent bone loss. Semaglutide and tirzepatide have specific indications for weight management and other conditions, depending on the product. Eligibility for one treatment does not establish eligibility for the other.

The review should therefore cover menopause symptoms, the uterus, bleeding, and hormone-related risks, alongside weight history, metabolic conditions, and the weight medicine's precautions. Two prescribers need access to the same medication list and relevant results.

Semaglutide and tirzepatide delay stomach emptying. Their labels advise reviewing possible effects on oral medicines. This does not establish that every hormone tablet becomes ineffective, but it creates a practical reason to review the exact formulation and schedule.

There is no standard HRT dose adjustment established by the Wegovy or Zepbound labels. Do not increase estrogen or progesterone on your own. Tell the prescriber if menopause symptoms return, if doses are missed, or if vomiting or prolonged diarrhea makes tablets difficult to take.

Wegovy tablets have their own timing instructions: take them on an empty stomach and wait at least 30 minutes before food, drink, or other oral medicines. The pharmacist can help organize morning medicines, especially levothyroxine, which has a documented interaction with oral semaglutide.

If you have a uterus and use systemic estrogen, a suitable progestogen is generally needed to protect the uterine lining. That applies to estrogen delivered by patch, gel, spray, or tablet. A skin patch changes the route of estrogen delivery; the lining still needs protection.

If oral progesterone is part of your regimen, review any difficulty taking or retaining it with the prescriber. They may consider a different regimen or delivery method according to your health history and local prescribing rules. A levonorgestrel intrauterine system is an option in some care plans, but its use for endometrial protection with estrogen is off-label in the United States.

Report new or persistent unscheduled bleeding. NICE guidance describes bleeding as common during the first six months of systemic HRT, or the first three months after a change, with prompt medical review beyond those periods. Heavy or concerning bleeding warrants earlier assessment.

HRT does not prevent pregnancy. If ovulation is still possible, contraception must be planned separately. Irregular periods during perimenopause do not reliably establish that pregnancy is no longer possible.

Zepbound may reduce the effectiveness of oral hormonal contraception. Its US label calls for a nonoral contraceptive method or an added barrier method for four weeks after treatment starts and four weeks after every dose increase. This precaution applies specifically to contraception and does not supply a tested dose adjustment for menopause hormones.

Weight treatment should be reviewed before a planned pregnancy. Wegovy should be stopped at least two months before trying to conceive. Zepbound should be discontinued when pregnancy is recognized, with pregnancy planning discussed in advance.

A 2024 retrospective study compared 106 postmenopausal women receiving semaglutide: 16 used hormone therapy and 90 did not. At 12 months, average weight loss was 16% in the hormone group and 12% in the other group. The association remained after adjustment for measured differences.

The small hormone group and nonrandom treatment assignment limit the conclusion. Differences in health, treatment selection, or other factors may contribute. This study cannot establish that adding HRT causes greater loss, and it did not test every GLP-1 medicine or hormone regimen.

Choose HRT for an established menopause-related indication. If both medicines are appropriate, judge each by its intended benefit, adverse effects, and ongoing suitability.

• Keep one dated list of the exact medicines, formulations, doses, and changes.
• Record whether a symptom followed a hormone change, an injection, or an increase in weight-medication dose.
• Tell both teams about persistent nausea, difficulty eating, missed progesterone, or unscheduled bleeding.
• Review adequate nutrition, strength work, and any glucose monitoring required by diabetes medicines.
• Tell the anesthesia team about GLP-1 treatment before a procedure.